Journal of Immunology Research / 2017 / Article / Tab 3

Research Article

Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation

Table 3

Patient characteristics in groups with and without PT.

PTWithout PT value

N32362
Patient age, median (range)36 (3–54)26 (2–58)0.020
Patient sex, male, n (%)17 (53.1)214 (59.1)0.320
Diagnosis, n (%)0.510
 AML13 (40.6)147 (40.6)
 ALL14 (43.8)119 (32.9)
 CML1 (3.1)21 (5.8)
 MDS3 (9.4)38 (10.5)
 Others1 (3.1)37 (10.2)
Disease risk, n (%)
 SR22 (68.8)279 (77.1)0.288
 HR10 (31.3)83 (22.9)
HLA incompatibility, n (%)0.533
 0 locus03 (0.8)
 1 locus2 (6.3)20 (5.5)
 2 loci4 (12.5)83 (22.9)
 3 loci26 (81.3)256 (70.7)
Donor-patient relation, n (%)0.260
 Sibling donor9 (28.1)108 (29.8)
 Father donor4 (12.5)53 (14.6)
 Mother donor9 (28.1)141 (39.0)
 Children donor9 (28.1)49 (13.5)
 Others1 (3.1)11 (3.0)
Donor-patient sex match, number (%)0.722
 Male to male11 (34.4)138 (38.1)
 Male to female11 (34.4)91 (25.1)
 Female to male6 (18.8)78 (21.5)
 Female to female4 (12.5)55 (15.2)
ABO matched, n (%)0.213
 Matched15 (46.9)209 (57.7)
 Major mismatched8 (25.0)66 (18.2)
 Minor mismatched5 (15.6)69 (19.1)
 Bidirect mismatched4 (12.5)18 (5.0)
Cell compositions in allografts, n (%)
 Infused nuclear cells ≥ median15 (46.9)181 (50.0)0.735
 Infused CD34+ cells ≥ median11 (34.4)187 (51.7)0.061
 Infused lymphocytes ≥ median13 (48.1)160 (50.3)0.829
 Infused CD3+ cells ≥ median14 (51.9)160 (50.3)0.878
 Infused CD4+ cells ≥ median16 (59.3)159 (50.0)0.356
 Infused CD8+ cells ≥ median16 (59.3)157 (49.4)0.324
 Infused CD14+ cells ≥ median16 (59.3)157 (49.4)0.324
Grade II–IV aGVHD12 (44.4)105 (33.0)0.229
cGVHD8 (25.0)120 (33.2)0.320
HLA antibody positive12 (37.5)87 (24.0)0.092
HLA-I antibody positive6 (18.8)57 (17.9)0.579
HLA-II antibody positive8 (25.0)49 (13.5)0.056
HLA-DP antibody positive3 (9.4)29 (8.0)0.732
DSA positive6 (18.8)39 (10.8)0.174
MFI > 10006 (18.6)31 (8.6)0.058
MFI > 20004 (12.5)27 (7.5)0.310

AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; SR: standard risk; HR: high risk; aGVHD: acute graft-versus-host disease; cGVHD: chronic graft-versus-host disease; HLA-I/II: class I/II HLA antibody; HLA-DP: class I and II HLA antibody double positive; DSA: donor-specific antibody; DSA-DP: class I and II DSA double positive; MFI: median fluorescent intensity.Bold means variates included in the multivariate analysis since their value < 0.1 in the univariate analysis.